COEP insider transaction filings
Coeptis Therapeutics Holdings, Inc. — 24 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-02-13. Screen COEP transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for COEP between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Coeptis Therapeutics Holdings, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-13 | 4 | Cogley Brian — Chief Financial Officer | Option exercise (M): 10,000 @ $10.56 · Grant/award (A): 12,500 @ $0 | EDGAR |
| 2026-02-13 | 4 | Calise Chris — Director | Option exercise (M): 5,700 @ $10.56 · Grant/award (A): 3,250 @ $0 | EDGAR |
| 2026-02-13 | 4 | Mehalick David — CEO and President, Director, 10% owner | Option exercise (M): 148,875 @ $7.05 · Grant/award (A): 51,250 @ $0 | EDGAR |
| 2026-02-13 | 4 | Yerace Daniel Alexander — VP Operations, Director | Option exercise (M): 10,000 @ $10.41 · Grant/award (A): 20,000 @ $0 | EDGAR |
| 2026-02-13 | 4 | DeSilva Tara — Director | Option exercise (M): 5,700 @ $10.56 · Grant/award (A): 3,250 @ $0 | EDGAR |
| 2026-02-13 | 4 | Cochran Christopher P. — Director | Option exercise (M): 5,700 @ $10.56 · Grant/award (A): 3,250 @ $0 | EDGAR |
| 2026-02-13 | 4 | Sheehy Christine Elise — VP Compliance and Secy | Option exercise (M): 1,000 @ $10.56 · Grant/award (A): 12,500 @ $0 | EDGAR |
| 2026-02-13 | 4 | Deschamps Philippe — Director | Option exercise (M): 5,700 @ $10.56 · Grant/award (A): 3,250 @ $0 | EDGAR |
| 2026-02-13 | 4 | Salkind Gene — Director | Option exercise (M): 5,700 @ $10.56 · Grant/award (A): 3,250 @ $0 | EDGAR |
| 2025-03-10 | 4 | Deschamps Philippe — Director | Grant/award (A): 5,700 (derivative) | EDGAR |
| 2025-03-06 | 4 | Cogley Brian — Chief Financial Officer | Grant/award (A): 10,000 (derivative) | EDGAR |
| 2025-03-06 | 4 | Yerace Daniel Alexander — VP of Operations, Director | Grant/award (A): 5,000 (derivative) | EDGAR |
| 2025-03-06 | 4 | Sheehy Christine Elise — VP Compliance and Secy | Grant/award (A): 1,000 (derivative) | EDGAR |
| 2025-03-06 | 4 | Mehalick David — CEO and President, Director, 10% owner | Grant/award (A): 28,875 (derivative) | EDGAR |
| 2025-03-06 | 4 | DeSilva Tara — Director | Grant/award (A): 5,700 (derivative) | EDGAR |
| 2025-03-06 | 4 | Cochran Christopher P. — Director | Grant/award (A): 5,700 (derivative) | EDGAR |
| 2025-03-06 | 4 | Calise Chris — Director | Grant/award (A): 5,700 (derivative) | EDGAR |
| 2025-03-06 | 4 | Salkind Gene — Director | Grant/award (A): 5,700 (derivative) | EDGAR |
| 2024-01-17 | 4 | Cogley Brian — Chief Financial Officer | Purchase (P): 5,000 @ $0.67 | EDGAR |
| 2024-01-16 | 4 | DeSilva Tara — Director | Purchase (P): 466 @ $0.56 · Purchase (P): 1,800 @ $0.58 | EDGAR |
| 2024-01-09 | 4 | Yerace Daniel Alexander — VP of Operations, Director | Purchase (P): 10,850 @ $0.69 | EDGAR |
| 2024-01-09 | 4 | Mehalick David — CEO and President, Director, 10% owner | Purchase (P): 5,050 @ $0.69 · Purchase (P): 6,000 @ $0.67 · Purchase (P): 14,004 @ $0.66 | EDGAR |
| 2024-01-09 | 4 | Cochran Christopher P. — Director | Purchase (P): 7,000 @ $0.77 | EDGAR |
| 2024-01-09 | 4 | Salkind Gene — Director | Purchase (P): 11,600 @ $0.69 | EDGAR |
Recent 8-K events — Coeptis Therapeutics Holdings, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-10 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 1.02 — Termination of a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=COEP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →